Addition of MPS-II to the Recommended Uniform Screening Panel in the United States
Conflicts of Interest
References
- DHHS adds MPS II to the RUSP for Newborn Screening in the United States. Available online: https://mpssociety.org/dhhs-adds-mps-ii-to-the-rusp-for-newborn-screening-in-the-united-states (accessed on 15 September 2022).
- Newborn Screening Status for All Disorders. Available online: https://www.newsteps.org/resources/data-visualizations/newborn-screening-status-all-disorders (accessed on 20 September 2022).
- Burton, B.K.; Hickey, R.; Hitchins, L. Newborn Screening for Mucopolysaccharidosis Type II in Illinois: An Update. Int. J. Neonatal Screen. 2020, 6, 73. [Google Scholar] [CrossRef] [PubMed]
- Bilyeu, H.; Washburn, J.; Vermette, L.; Klug, T. Validation and Implementation of a Highly Sensitive and Efficient Newborn Screening Assay for Mucopolysaccharidosis Type II. Int. J. Neonatal Screen. 2020, 6, 79. [Google Scholar] [CrossRef] [PubMed]
- Lin, H.-Y.; Chang, Y.-H.; Lee, C.-L.; Tu, Y.-R.; Lo, Y.-T.; Hung, P.-W.; Niu, D.-M.; Liu, M.-Y.; Liu, H.-Y.; Chen, H.-J.; et al. Newborn Screening Program for Mucopolysaccharidosis Type II and Long-Term Follow-Up of the Screen-Positive Subjects in Taiwan. J. Pers. Med. 2022, 12, 1023. [Google Scholar] [CrossRef] [PubMed]
- Nominate a Condition. Available online: https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/nominate (accessed on 15 September 2022).
- Summary of Nominated Conditions to the Recommended Uniform Screening Panel (RUSP). Available online: https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/summary-nominated-conditions-may-2022.pdf (accessed on 15 September 2022).
- Advisory Committee on Heritable Disorders in Newborns and Children Votes to Approve MPS II for Recommended Uniform Screening Panel. Available online: https://mpssociety.org/wp-content/uploads/2022/02/2-11-2022-MPS-II-RUSP-Announcement-Final.pdf (accessed on 15 September 2022).
- The Recommended Uniform Screening Panel. Available online: https://babysfirsttest.org/newborn-screening/the-recommended-uniform-screening-panel (accessed on 15 September 2022).
- Wilcken, B. Newborn Screening for Lysosomal Disease: Mission Creep and a Taste of Things to Come? Int. J. Neonatal Screen. 2018, 4, 21. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sawamoto, K.; Stapleton, M.; Alméciga-Díaz, C.J.; Espejo-Mojica, A.J.; Losada, J.C.; Suarez, D.A.; Tomatsu, S. Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments. Drugs 2019, 79, 1103–1134. [Google Scholar] [CrossRef] [PubMed]
- Lampe, C.; Atherton, A.; Burton, B.K.; Descartes, M.; Giugliani, R.; Horovitz, D.D.; Kyosen, S.O.; Magalhães, T.S.; Martins, A.M.; Mendelsohn, N.J.; et al. Enzyme Replacement Therapy in Mucopolysaccharidosis II Patients Under 1 Year of Age. J. Inherit. Metab. Dis. Rep. 2014, 14, 99–113. [Google Scholar]
- Kubaski, F.; Vairo, F.; Baldo, G.; de Oliveira, P.F.; Corte, D.A.; Giugliani, R. Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease). Curr. Pharm. Des. 2020, 26, 5100–5109. [Google Scholar] [CrossRef] [PubMed]
- Giugliani, R.; Martins, A.M.; Okuyama, T.; Eto, Y.; Sakai, N.; Nakamura, K.; Morimoto, H.; Minami, K.; Yamamoto, T.; Yamaoka, M.; et al. Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data. Int. J. Mol. Sci. 2021, 22, 10938. [Google Scholar] [CrossRef] [PubMed]
- Ullman, J.C.; Arguello, A.; Getz, J.A.; Bhalla, A.; Mahon, C.S.; Wang, J.; Giese, T.; Bedard, C.; Kim, D.J.; Blumenfeld, J.R.; et al. Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice. Sci. Transl. Med. 2020, 12, eaay1163. [Google Scholar] [CrossRef] [PubMed]
- Giugliani, R.; Harmatz, P.; Ficicioglu, C.; Escolar, M.L.; Fiscella, M.; Yang, L.; Phillips, D.; Falabella, P. RGX-121 gene therapy for the treatment of severe mucopolysaccharidosis type II (MPS II): Interim analysis of data from a Phase 1/2 study. Mol. Ther. 2022, 30, 4S1. [Google Scholar]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Millington, D.S.; Ficicioglu, C. Addition of MPS-II to the Recommended Uniform Screening Panel in the United States. Int. J. Neonatal Screen. 2022, 8, 55. https://doi.org/10.3390/ijns8040055
Millington DS, Ficicioglu C. Addition of MPS-II to the Recommended Uniform Screening Panel in the United States. International Journal of Neonatal Screening. 2022; 8(4):55. https://doi.org/10.3390/ijns8040055
Chicago/Turabian StyleMillington, David S., and Can Ficicioglu. 2022. "Addition of MPS-II to the Recommended Uniform Screening Panel in the United States" International Journal of Neonatal Screening 8, no. 4: 55. https://doi.org/10.3390/ijns8040055